| Document |
Document Title |
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
|
WO/2022/092260A1 |
The present invention addresses the problem of providing a cross-coupling reaction method that can use a wide variety of compounds as starting materials, that can substantially not use organic solvent, and that can rapidly provide reacti...
|
|
WO/2022/089598A1 |
A flavonoid glycoside and organic amine neuroagonist double salt compound, a preparation method therefor, and an application thereof, a pharmaceutical composition containing a therapeutically effective amount of the double salt compound ...
|
|
WO/2022/076507A1 |
The present disclosure relates to compounds that are capable of inhibiting PRMT8 and/or upregulating SirTl. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease).
|
|
WO/2022/061920A1 |
A method for preparing 3',5'-dichloro-2,2,2-trifluoroacetophenone. The method comprises subjecting 3'-chloro-2,2,2-trifluoroacetophenone as a raw material to four steps, i.e. nitrification, reduction, chlorination and deamination, so as ...
|
|
WO/2022/061914A1 |
The present application relates to the technical field of chemical pharmacy, and in particular, to a method for preparing 3,5-dihalotrifluoroacetophenone and a derivative thereof. 3-halogen-4-nitrotrifluoroacetophenone is used as a raw m...
|
|
WO/2022/058916A1 |
The present invention disclosed a process for the synthesis of compound of formula (Z) or a salt thereof, wherein, R, R1, R2, R3 and R10 are as defined in the detailed description. The process further comprises the synthesis of an anthra...
|
|
WO/2022/014344A1 |
Provided is a thin film-forming material containing a yttrium compound represented by general formula (1). (In the formula, R1 and R3 each independently represent an alkyl group having 1-6 carbon atoms or an alkoxyalkyl group having 2-...
|
|
WO/2021/255737A1 |
The present disclosure pertains to amino cyclohexanone compounds, pharmaceutical compositions containing same and methods of treating depression, pain, inflammation, and other clinical indications.
|
|
WO/2021/234697A1 |
The present invention pertains to compositions and methods for treating inflammation in a subject in need thereof using hydroxynorketamine (HNK), a salt thereof, a stereoisomer thereof, or a combination thereof.
|
|
WO/2021/233805A1 |
The present invention relates to a process for purifying 2-(4'-diethylamino-2'-hydroxybenzoyl)benzoic acid hexyl ester providing a high purity and low phthalic acid dialkyl ester content.
|
|
WO/2021/212974A1 |
A racemic and chiral 3-(2,3-butadienyl)oxyindolinone compound, a method for preparing the compound using a palladium catalyzed coupling reaction and an application thereof. According to the preparation method, 2,3-butadienyl carbonate an...
|
|
WO/2021/208951A1 |
Disclosed is a β-diketone cerium (IV) compound of formula (I). The compound has a wide absorption band, is suitable for near ultraviolet-visible region curing as a photoinitiator, and has a high sensitiveness, while also having the adva...
|
|
WO/2021/071033A9 |
The present invention relates to a method for preparing diethylamino hydroxybenzoyl hexyl benzoate and, specifically, to: a method for preparing diethylamino hydroxybenzoyl hexyl benzoate, which has a simple preparation process and can b...
|
|
WO/2021/189528A1 |
Disclosed are a thermally activated delayed fluorescent material and a synthesis method therefor, and an electroluminescent device. The thermally activated delayed fluorescent material is a target compound synthesized by reaction of an e...
|
|
WO/2021/175901A1 |
The present invention relates to the technical field of pharmaceutical synthesis and development of drugs, and to a process for preparing cyclic 2-amino-1-one derivatives and to the reaction products and intermediates obtainable by this ...
|
|
WO/2021/142062A1 |
Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared t...
|
|
WO/2021/134820A1 |
Disclosed are a new organic electroluminescent compound and an organic electroluminescent device. The structural formula of the organic electroluminescent compound is as shown below: (I), wherein L1 and L2 are phenylene, and L1 and L2 ma...
|
|
WO/2021/138443A1 |
Methods and compositions for modifying the course and severity of neuropsychiatric disorders. The method includes administering a composition to a subject suffering from a neuropsychiatric disorder, wherein the composition includes a sub...
|
|
WO/2021/134086A1 |
Provided herein are arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders.
|
|
WO/2021/105356A1 |
The invention concerns new keto-ammonium compounds with surfactant properties and improved biodegradability.
|
|
WO/2021/103728A1 |
An organic compound and an organic electroluminescent device using the compound used for the field of organic electroluminescence. The organic compound is as shown in structural formula I, wherein Ar1 to Ar 4 are independently selected f...
|
|
WO/2021/101867A1 |
The disclosure provides salts of (2R,6R)-hydroxynorketamine (HNK), wherein the salt is with an organic acid chosen from malonic acid, salicylic acid, ethane sulfonic acid, glycolic acid, stearic acid, or capric acid, and their crystal fo...
|
|
WO/2020/251015A1 |
Provided is a method for producing a substance related to 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione that is suitable for industrial production. The present disclosure provides: a method for producing two production intermediates for 2...
|
|
WO/2020/237749A1 |
Provided is a compound having a long-acting therapeutic effect. The compound can be used to prepare an antidepressant drug and drugs for anesthesia, analgesia, improvement of cognitive function, lung protection, amyotrophic lateral scler...
|
|
WO/2020/239942A1 |
The invention relates to 1,4-diaminoanthraquinones and an electrolyte, and their use in batteries.
|
|
WO/2020/237748A1 |
Provided in the present application is a method for preparing a compound having a long-acting therapeutic effect. The compound may be used to prepare antidepressant, anesthetic and analgesic drugs, as well as drugs for cognitive function...
|
|
WO/2020/232274A1 |
Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.
|
|
WO/2020/227168A1 |
The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with th...
|
|
WO/2020/215388A1 |
Provided are a deep red light thermally activated delayed fluorescence material, a preparation method therefor, and an electroluminescent device. The deep red light thermally activated delayed fluorescence (TADF) material comprises a com...
|
|
WO/2020/212510A1 |
The present invention is directed to methods for the asymmetric synthesis of esketamine. The present invention is further directed to key intermediates in the asymmetric esketamine synthesis. In one embodiment, the invention is an asymme...
|
|
WO/2020/212157A1 |
The invention concerns a new, efficient process for the preparation of enantiomerically pure norepinephrine (also known as noradrenaline), or an addition salt thereof, using a catalytic hydrogenation system under hydrogen donor transfer....
|
|
WO/2020/212399A1 |
The present invention relates to a method for the preparation of the preparation of ethyl (2S, 3S)-3-aminobicyclo [2.2.2] octane-2 -carboxylate from the β-keto ester (II) via a chiral transfer hydrogenation reaction in the presence of a...
|
|
WO/2020/212890A1 |
Disclosed herein is a method for synthesizing levomethadone hydrochloride including producing (R)-2-(dimethylamino)propan-1-ol by reducing Ν,Ν-dimethyl-D-alanine using borax, forming (R)-1-chloro-N,N-dimethylpropane-2-amine hydrochlori...
|
|
WO/2020/192348A1 |
Disclosed are phenyl allylidene cyclohexenone derivatives with the structure shown in general formula I. In combination with structural characteristics and structure-function relationship of piplartine, amino bonds are replaced with doub...
|
|
WO/2020/187155A1 |
Use of an apocynin dimer analogue derivative in preparing a medicament or a health care product for preventing and treating Parkinson's disease. The structure of the apocynin dimer analogue derivative is as shown in formula I. The apocyn...
|
|
WO/2020/172749A1 |
Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as metho...
|
|
WO/2020/169054A1 |
The present invention relates to crystalline forms I and II of a (E)-α,β-unsatured amide compound, preparation methods therefor, and uses thereof. The crystalline forms all have excellent properties in physical and chemical stability a...
|
|
WO/2020/163612A1 |
Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the ...
|
|
WO/2020/159587A1 |
Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The stru...
|
|
WO/2020/037372A1 |
A method of detecting the presence of an NBOMe in a sample which comprises of contacting the sample with an activated p-quinone such as 2,3,5,6-tetrachloro-1,4-benzoquinone (TCBQ) and an aldehyde, for example acetaldehyde, and optionally...
|
|
WO/2020/008051A1 |
The present invention relates to a compound of the following formula (I): (I). The invention also relates to uses thereof as dye or pigment, notably as a luster pigment,and to areflective or photonic or nanophotonic or optoelectronic dev...
|
|
WO/2020/003022A1 |
Described are polymerizable high energy light absorbing compounds of formula I: Wherein Y, Pg, R1, R2, R3, R4, R5, and R6 are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light a...
|
|
WO/2020/002338A1 |
A process for the continuous production of a reaction product of a diazo‐compound and a substrate in a multi‐stage flow reactor is disclosed.
|
|
WO/2019/236557A1 |
A process for the preparation of (2R,6R)-hydroxynorketamine is provided. The process requires no chromatography purification and affords the (2R,6R)-hydroxynorketamine in eight steps with a 26% overall yield and greater than 97% purity.
|
|
WO/2019/223015A1 |
Disclosed are a precursor for a blue anthraquinone active disperse dye and a preparation method therefor. A parent body structure of the precursor is of an anthraquinone structure, has an amino capable of being reacted with an active gro...
|
|
WO/2019/223016A1 |
Provided are a blue anthraquinone active disperse dye suitable for use in a supercritical CO2 fluid dyeing process and a preparation method therefor. A parent structure of the active disperse dye is of an anthraquinone structure, and als...
|
|
WO/2019/219942A1 |
Provided is a process for producing an amine via a hydroaminoalkylation reaction of a non-aromatic C-C double bond or C-C triple bond, said process comprising a step of reacting a compound comprising a non-aromatic C-C double bond or C-C...
|
|
WO/2019/213551A1 |
The disclosure provides a method of treating a substance use disorder in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising R(-)-ketamine or a pharmaceutically acceptable sal...
|
|
WO/2019/199518A1 |
Processes are disclosed for synthesizing an α-amino acid or α-amino acid derivative, from a starting compound having a carbonyl functional group (C=O), with hydroxy-substituted carbon atoms at alpha (α) and beta (β) positions, relati...
|
